Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Clinical evidence

COMP006

68 evidence topics · 26 sources

Objective
Location and study date
Study design
Eligibility criteria
Key inclusion criteria
Treatment
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics
CharacteristicCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Female, n (%)“160 (54.1)”“68 (47.9)”“69 (48.3)”
White, n (%)“255 (86.1)”“123 (86.6)”“129 (90.2)”
Asian, n (%)“14 (4.7)”“6 (4.2)”“6 (4.2)”
Black or African American, n (%)“8 (2.7)”“3 (2.1)”“4 (2.8)”
American Indian or Alaska Native, n (%)“0”“0”“1 (0.7)”
Other/not reported, n (%)“19 (6.4)”“10 (7.0)”“3 (2.1)”
Age, years, mean (SD)“46.2 (13.7)”“42.9 (12.8)”“45.5 (13.1)”
Age, min, max“18, 79”“19, 73”“20, 75”
Age ≥65 years, n (%)“29 (9.8)”“9 (6.3)”“13 (9.1)”
Prior psilocybin experience, n (%)“12 (4.1)”“5 (3.5)”“5 (3.5)”
Prior psychedelic experience including psilocybin, n (%)“20 (6.8)”“8 (5.6)”“9 (6.3)”
BMI, kg/m2, mean (SD)“28.0 (6.2)”“28.4 (6.4)”“28.0 (6.5)”
Treatment history and baseline MADRS
CharacteristicCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Failed treatments in current episode: 1, n (%)“1 (0.3)”“1 (0.7)”“0”
Failed treatments in current episode: 2, n (%)“190 (64.2)”“105 (73.9)”“98 (68.5)”
Failed treatments in current episode: 3, n (%)“74 (25.0)”“32 (22.5)”“34 (23.8)”
Failed treatments in current episode: 4, n (%)“29 (9.8)”“4 (2.8)”“11 (7.7)”
Failed treatments in current episode: 5, n (%)“2 (0.7)”“0”“0”
Treatments withdrawn in screening: 0, n (%)“68 (23.0)”“30 (21.1)”“36 (25.2)”
Treatments withdrawn in screening: 1, n (%)“127 (42.9)”“62 (43.7)”“62 (43.4)”
Treatments withdrawn in screening: 2, n (%)“68 (23.0)”“34 (23.9)”“31 (21.7)”
Treatments withdrawn in screening: more than 2, n (%)“33 (11.1)”“16 (11.3)”“14 (9.8)”
MADRS total score at baseline, mean (SD)“32.0 (5.8)”“32.1 (5.8)”“32.5 (5.4)”
Baseline MADRS subthreshold (≤10), n (%)“2 (0.7)”“0”“0”
Baseline MADRS mild (11-19), n (%)“0”“0”“0”
Baseline MADRS moderate (20-30), n (%)“115 (38.9)”“54 (38.0)”“49 (34.3)”
Baseline MADRS severe (≥31), n (%)“179 (60.5)”“88 (62.0)”“94 (65.7)”
Depression diagnosis history
CharacteristicCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Length of current episode, months, mean (SD)“45.5 (42.7)”“37.7 (38.8)”“38.4 (45.0)”
Length of current episode less than 1 year, n (%)“53 (17.9)”“37 (26.1)”“30 (21.0)”
Length of current episode 1-2 years, n (%)“73 (24.7)”“35 (24.6)”“41 (28.7)”
Length of current episode more than 2 years, n (%)“170 (57.4)”“70 (49.3)”“72 (50.3)”
Lifetime depressive episodes, mean (SD)“6.3 (7.4)”“5.4 (6.6)”“7.0 (12.5)”
Lifetime depressive episodes: 1, n (%)“1 (0.3)”“0”“0”
Lifetime depressive episodes: 2-5, n (%)“199 (67.2)”“109 (76.8)”“99 (69.2)”
Lifetime depressive episodes: 6-10, n (%)“61 (20.6)”“21 (14.8)”“30 (21.0)”
Lifetime depressive episodes: more than 10, n (%)“29 (9.8)”“10 (7.0)”“10 (7.0)”
Baseline values that differ in the February 2026 presentation
CharacteristicCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Prior psilocybin experience, n (%)“13 (4.4)”“5 (3.5)”“5 (3.5)”
Prior psychedelic experience including psilocybin, n (%)“19 (6.4)”“7 (4.9)”“9 (6.3)”
BMI, kg/m2, mean (SD)“28.0 (6.2)”“28.6 (7.1)”“27.8 (6.7)”
Failed treatments in current episode: 2, n (%)“190 (64.2)”“105 (73.9)”“99 (69.2)”
Failed treatments in current episode: 3, n (%)“74 (25.0)”“32 (22.5)”“33 (23.1)”
Treatments withdrawn in screening: 0, n (%)“68 (23.0)”“31 (21.8)”“36 (25.2)”
Treatments withdrawn in screening: 1, n (%)“127 (42.9)”“61 (43.0)”“62 (43.4)”
Treatments withdrawn in screening: 2, n (%)“68 (23.0)”“35 (24.6)”“31 (21.7)”
Treatments withdrawn in screening: more than 2, n (%)“33 (11.1)”“15 (10.6)”“14 (9.8)”
Lifetime depressive episodes: 2-5, n (%)“198 (66.9)”“109 (76.8)”“99 (69.2)”
Efficacy results
Part A key secondary endpoint: MADRS change at Week 9
Visit25 mg vs 1 mg, LS mean difference (95% CI)25 mg vs 1 mg, P-value10 mg vs 1 mg, LS mean difference (95% CI)10 mg vs 1 mg, P-value
Week 6 (primary)“-3.8 (-5.8, -1.8)”“<0.001”“-2.5 (-4.9, -0.2)”“0.016”
Week 9 (secondary)“-2.9 (-5.0, -0.9)”“0.002”“-2.6 (-5.0, -0.2)”“0.016”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Part A treatment-emergent adverse events through Week 9
MeasureCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Any TEAE up to Week 9, n (%)“274 (92.6)”“125 (88.0)”“116 (81.1)”
Any serious TEAE up to Week 9, n (%)“6 (2.0)”“1 (0.7)”“5 (3.5)”
Any TEAE with onset on day of dosing, n (%)“260 (87.8)”“114 (80.3)”“80 (55.9)”
Resolved ≤1 day, n (%)“244 (82.4)”“107 (75.4)”“71 (49.7)”
Resolved >1 and ≤2 days, n (%)“52 (17.6)”“16 (11.3)”“9 (6.3)”
Resolved >2 days, n (%)“71 (24.0)”“26 (18.3)”“20 (14.0)”
Part A TEAEs with incidence above 10%
MedDRA preferred termCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Any TEAE, n (%)“254 (85.8)”“111 (78.2)”“80 (55.9)”
Nausea, n (%)“118 (39.9)”“42 (29.6)”“15 (10.5)”
Headache, n (%)“108 (36.5)”“43 (30.3)”“41 (28.7)”
Anxiety, n (%)“62 (20.9)”“28 (19.7)”“21 (14.7)”
Hallucination, visual, n (%)“46 (15.5)”“24 (16.9)”“3 (2.1)”
Illusion, n (%)“41 (13.9)”“16 (11.3)”“3 (2.1)”
Dizziness, n (%)“41 (13.9)”“21 (14.8)”“9 (6.3)”
Fatigue, n (%)“41 (13.9)”“23 (16.2)”“16 (11.2)”
Crying, n (%)“35 (11.8)”“13 (9.2)”“4 (2.8)”
Blood pressure increased, n (%)“31 (10.5)”“6 (4.2)”“4 (2.8)”
Part A treatment-emergent serious adverse events
MedDRA preferred termCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Any SAE, n (%)“6 (2.0)”“1 (0.7)”“5 (3.5)”
Suicidal ideation, n (%)“0”“1 (0.7)”“2 (1.4)”
Suicidal behaviour, n (%)“0”“0”“1 (0.7)”
Syncope, n (%)“1 (0.3)”“0”“1 (0.7)”
Major depression, n (%)“1 (0.3)”“0”“0”
Anxiety, n (%)“1 (0.3)”“0”“0”
Flashback, n (%)“1 (0.3)”“0”“0”
Cervical spinal stenosis, n (%)“1 (0.3)”“0”“0”
Renal neoplasm, n (%)“0”“0”“1 (0.7)”
Pelvic pain, n (%)“1 (0.3)”“0”“0”
Treatment-emergent adverse events through Week 26
MeasureCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Any TEAE up to Week 26, n (%)“280 (94.6)”“132 (93.0)”“124 (86.7)”
Any serious TEAE up to Week 26, n (%)“17 (5.7)”“5 (3.5)”“9 (6.3)”
Any TEAE with onset on day of dosing, n (%)“265 (89.5)”“119 (83.8)”“88 (61.5)”
Resolved ≤1 day, n (%)“255 (86.1)”“113 (79.6)”“78 (54.5)”
Resolved >1 and ≤2 days, n (%)“60 (20.3)”“22 (15.5)”“12 (8.4)”
Resolved >2 days, n (%)“80 (27.0)”“32 (22.5)”“21 (14.7)”
Nausea, n (%)“133 (44.9)”“50 (35.2)”“18 (12.6)”
Headache, n (%)“118 (39.9)”“53 (37.3)”“49 (34.3)”
Anxiety, n (%)“83 (28.0)”“38 (26.8)”“29 (20.3)”
Hallucination, visual, n (%)“51 (17.2)”“27 (19.0)”“5 (3.5)”
Fatigue, n (%)“49 (16.6)”“26 (18.3)”“19 (13.3)”
Illusion or perceptual disturbance, n (%)“48 (16.2)”“19 (13.4)”“4 (2.8)”
Dizziness, n (%)“47 (15.9)”“25 (17.6)”“9 (6.3)”
Crying, n (%)“41 (13.9)”“15 (10.6)”“6 (4.2)”
Blood pressure increased, n (%)“35 (11.8)”“10 (7.0)”“4 (2.8)”
Treatment-emergent serious adverse events through Week 26
MedDRA preferred termCOMP360 25 mg (N=296)COMP360 10 mg (N=142)COMP360 1 mg (N=143)
Any TESAE, n (%)“17 (5.7)”“5 (3.5)”“9 (6.3)”
Suicidal ideation, n (%)“4 (1.4)”“2 (1.4)”“4 (2.8)”
Suicidal behaviour, n (%)“0”“0”“1 (0.7)”
Suspected suicide, n (%)“1 (0.3)”“0”“0”
Suicide attempt, n (%)“0”“0”“1 (0.7)”
Syncope, n (%)“1 (0.3)”“0”“1 (0.7)”
Major depression, n (%)“1 (0.3)”“0”“0”
Anxiety, n (%)“1 (0.3)”“0”“0”
Flashback, n (%)“1 (0.3)”“0”“0”
Cervical spinal stenosis, n (%)“1 (0.3)”“0”“0”
Renal neoplasm, n (%)“0”“0”“1 (0.7)”
Pelvic pain, n (%)“1 (0.3)”“0”“0”
Adjustment disorder with mixed disturbance of emotion and conduct, n (%)“1 (0.3)”“0”“0”
Pneumonia, n (%)“0”“1 (0.7)”“0”
Radius fracture, n (%)“1 ( 0.3)”“1 (0.7)”“0”
Road traffic accident, n (%)“1 ( 0.3)”“0”“0”
Tibia fracture, n (%)“1 ( 0.3)”“0”“0”
Ulna fracture, n (%)“1 ( 0.3)”“0”“0”
Alanine aminotransferase increased, n (%)“1 ( 0.3)”“0”“0”
Aspartate aminotransferase increased, n (%)“1 ( 0.3)”“0”“0”
Brain neoplasm, n (%)“1 (0.3)”“0”“0”
Thyroid neoplasm, n (%)“1 (0.3)”“0”“0”
Cerebrovascular accident, n (%)“0”“0”“1 (0.7)”
Toxic encephalopathy, n (%)“0”“1 (0.7)”“0”
Tremor, n (%)“1 (0.3)”“0”“0”
Study limitations
Summary: functional unblinding, low-dose comparator, post hoc and observed-case analyses, preliminary data

COMP006 used COMP360 1 mg as the comparator to address “some of the functional unblinding risks of an inert placebo-control”. FDA guidance states that functional unblinding can lead to expectation bias and that enrolling participants with prior psychedelic exposure raises the possibility of expectation bias; the planned limit for prior psychedelic experience in COMP006 was 15%. One analysis found that outcomes with extremely low dose psilocybin were better than placebo response in psychedelic trials (mean difference 3.96), and a review reported that psilocybin, LSD, and ayahuasca studies “frequently reported blinding failure values of more than 90%” among participants and raters. The responder analysis is post hoc, Part B results after Week 9 are observed data, and protocol-allowed antidepressants were permitted in Parts B and C. The company describes the 26-week results as preliminary and states that full results may not be consistent with them; the registry shows no results posted.